Theravance Biopharma Inc. (NASDAQ:TBPH)’s share price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $27.90 and last traded at $27.82, with a volume of 198,411 shares trading hands. The stock had previously closed at $26.96.

Several brokerages recently issued reports on TBPH. Leerink Swann reissued a “buy” rating on shares of Theravance Biopharma in a report on Saturday, June 4th. Zacks Investment Research lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 19th. Bank of America Corp. downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Thursday, May 5th. Finally, Guggenheim started coverage on shares of Theravance Biopharma in a research note on Monday, June 20th. They issued a “buy” rating and a $30.00 target price for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $29.00.

The stock’s market capitalization is $1.34 billion. The firm’s 50 day moving average is $23.89 and its 200 day moving average is $20.56.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.05) by $0.01. Analysts anticipate that Theravance Biopharma Inc. will post ($4.03) EPS for the current year.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.